openPR Logo
Press release

Hereditary Transthyretin Amyloidosis (hATTR) Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Eidos, Corino, Prothena, Ionis Pharma, AstraZeneca, Novo Nordisk

10-03-2025 03:48 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hereditary Transthyretin Amyloidosis (hATTR) Market

The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, Intellia Therapeutics, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others.

DelveInsight's "Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hereditary Transthyretin Amyloidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Transthyretin Amyloidosis Market Forecast [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hereditary Transthyretin Amyloidosis Market Report:

*
The Hereditary Transthyretin Amyloidosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In September 2025, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a clinical-stage gene editing company advancing CRISPR-based therapies, announced longer-term follow-up data from its ongoing Phase 1 study of nexiguran ziclumeran (nex-z) for treating hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The findings were presented in an oral session on September 25 at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors in Baveno, Italy. The results were also published in the New England Journal of Medicine, and the presentation is available on the Scientific Publications & Presentations section of intelliatx.com.

*
In August 2025, Prothena Corporation announced that Novo Nordisk, during its Q2 2025 update, confirmed plans to advance coramitug, a potential first-in-class amyloid-clearing antibody, into a Phase III trial for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Originally developed by Prothena, coramitug was acquired by Novo Nordisk in July 2021.

*
In June 2025, Alnylam Pharmaceuticals announced that the European Commission (EC) has approved an expanded indication for AMVUTTRA (vutrisiran), an orphan RNAi therapy, for treating wild-type or hereditary transthyretin amyloidosis (ATTR-CM) in adult patients with cardiomyopathy.

*
In November 2024, Intellia Therapeutics, Inc. (NASDAQ:NTLA), a prominent clinical-stage gene editing company specializing in CRISPR-based therapies, has announced promising new clinical data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z, also referred to as NTLA-2001) in patients with transthyretin (ATTR) amyloidosis. Nex-z is an experimental in vivo CRISPR-based gene editing treatment under investigation as a one-time therapy for ATTR amyloidosis. Intellia leads the development and commercialization of nex-z in collaboration with Regeneron.

*
In October 2024, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that WAINZUA (eplontersen), developed in collaboration with AstraZeneca, has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for treating hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, also known as hATTR-PN or ATTRv-PN. If approved by the European Commission, WAINZUA will become the first and only medicine in the EU for treating ATTRv-PN that can be self-administered monthly using an auto-injector.

*
In January 2024, WAINUA Trademark (eplontersen) is a self-administered auto-injector treatment designed for managing the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR-PN or ATTRv-PN) in adult patients. Developed by Ionis Pharmaceuticals, a biotech firm headquartered in the United States, WAINUA Trademark utilizes Ionis' sophisticated LIgand-Conjugated Antisense (LICA) technology to regulate the production of transthyretin (TTR) protein. This therapeutic approach aims to address the underlying pathology of ATTR for improved patient outcomes.

*
The current treatment landscape includes several US FDA-approved therapies, such as AMVUTTRA (vutrisiran), ONPATTRO (patisiran), TEGSEDI (inotersen), VYNDAQEL (tafamidis meglumine), VYNDAMAX (tafamidis), WAINUA (eplontersen), among others.

*
In 2024, the United States represented nearly 65% of the total diagnosed prevalent cases of hATTR across the 7MM, and this figure is projected to rise further by 2034.

*
The most frequently observed hATTR variants in the United States include TTR V30M, TTR T60A, TTR L58H, TTR S77Y, and TTR I84S.

*
Approximately 45% of hATTR cases in the United States are attributed to familial amyloid polyneuropathy (FAP).

*
Key Hereditary Transthyretin Amyloidosis Companies: Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, Intellia Therapeutics, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others

*
Key Hereditary Transthyretin Amyloidosis Therapies: AMVUTTRA (vutrisiran), WAINUA (eplontersen), ONPATTRO (patisiran), TEGSEDI (inotersen), Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others

*
The Hereditary Transthyretin Amyloidosis epidemiology based on gender analyzed that FAP is the most affected type-specific hATTR in the US

*
The Hereditary Transthyretin Amyloidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Transthyretin Amyloidosis pipeline products will significantly revolutionize the Hereditary Transthyretin Amyloidosis market dynamics.

Hereditary Transthyretin Amyloidosis Overview

Hereditary Transthyretin Amyloidosis (hATTR), also known as transthyretin amyloidosis or ATTRv amyloidosis, is a rare, inherited disorder characterized by the accumulation of abnormal deposits of a protein called transthyretin (TTR) in various tissues and organs throughout the body.

Get a Free sample for the Hereditary Transthyretin Amyloidosis Market Report:

https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market [https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hereditary Transthyretin Amyloidosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hereditary Transthyretin Amyloidosis Epidemiology Segmentation:

The Hereditary Transthyretin Amyloidosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hereditary Transthyretin Amyloidosis

*
Prevalent Cases of Hereditary Transthyretin Amyloidosis by severity

*
Gender-specific Prevalence of Hereditary Transthyretin Amyloidosis

*
Diagnosed Cases of Episodic and Chronic Hereditary Transthyretin Amyloidosis

Download the report to understand which factors are driving Hereditary Transthyretin Amyloidosis epidemiology trends @ Hereditary Transthyretin Amyloidosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hereditary Transthyretin Amyloidosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis market or expected to get launched during the study period. The analysis covers Hereditary Transthyretin Amyloidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Transthyretin Amyloidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hereditary Transthyretin Amyloidosis Therapies and Key Companies

*
AMVUTTRA (vutrisiran): Alnylam Pharmaceuticals

*
WAINUA (eplontersen): AstraZeneca/Ionis Pharmaceuticals

*
ONPATTRO (patisiran): Alnylam Pharmaceuticals

*
TEGSEDI (inotersen): Ionis Pharmaceuticals

*
Nexiguran Ziclumeran: Intellia Therapeutics

*
ALXN2220 (formerly NI006): Neurimmune/Alexion Pharmaceuticals

*
Coramitug: Novo Nordisk

*
CRX-1008 (Tolcapone; SOM0226): Corino Therapeutics

*
PRX004: Prothena/ Novo Nordisk

*
NTLA-2001: Intellia Therapeutics/Regeneron Pharmaceutical

*
Eplontersen: Ionis Pharmaceuticals/ AstraZeneca

*
Acoramidis (AG 10): Eidos Therapeutics

Discover more about therapies set to grab major Hereditary Transthyretin Amyloidosis market share @ Hereditary Transthyretin Amyloidosis Treatment Market [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hereditary Transthyretin Amyloidosis Market Strengths

*
The development and success of gene silencing therapies in hATTR amyloidosis is a breakthrough for adult-onset, neurodegenerative diseases.

*
The upcoming therapies with their novel mechanism of action hold potential to combat the unmet need faced by the patients with hATTR-CM and hATTR-PN and provide better treatment options to the patients.

*
The upcoming pipeline also includes a gene therapy based on CRISPR technology, which is currently in early phase of development. If this therapy gets approved, it could provide a cure for hATTR.

Hereditary Transthyretin Amyloidosis Market Opportunities

*
The unique mechanisms of action of inotersen and patisiran overcome many limitations of previous therapies for patients with hATTR.

*
Currently there is only one therapy approved for ATTR-CM in the 7MM, i.e., Vandaqel, this provides a window of opportunity for key players to develop therapies targeting ATTR-CM.

*
Additional evidence for current and emerging therapies for patients with hATTR offers muchneeded hope, along with a promise of better treatment, for this debilitating and lifethreatening disease.

Scope of the Hereditary Transthyretin Amyloidosis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hereditary Transthyretin Amyloidosis Companies: Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, Intellia Therapeutics, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others

*
Key Hereditary Transthyretin Amyloidosis Therapies: AMVUTTRA (vutrisiran), WAINUA (eplontersen), ONPATTRO (patisiran), TEGSEDI (inotersen), Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others

*
Hereditary Transthyretin Amyloidosis Therapeutic Assessment: Hereditary Transthyretin Amyloidosis current marketed and Hereditary Transthyretin Amyloidosis emerging therapies

*
Hereditary Transthyretin Amyloidosis Market Dynamics: Hereditary Transthyretin Amyloidosis market drivers and Hereditary Transthyretin Amyloidosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hereditary Transthyretin Amyloidosis Unmet Needs, KOL's views, Analyst's views, Hereditary Transthyretin Amyloidosis Market Access and Reimbursement

To know more about Hereditary Transthyretin Amyloidosis companies working in the treatment market, visit @ Hereditary Transthyretin Amyloidosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hereditary Transthyretin Amyloidosis Market Report Introduction

2. Executive Summary for Hereditary Transthyretin Amyloidosis

3. SWOT analysis of Hereditary Transthyretin Amyloidosis

4. Hereditary Transthyretin Amyloidosis Patient Share (%) Overview at a Glance

5. Hereditary Transthyretin Amyloidosis Market Overview at a Glance

6. Hereditary Transthyretin Amyloidosis Disease Background and Overview

7. Hereditary Transthyretin Amyloidosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Transthyretin Amyloidosis

9. Hereditary Transthyretin Amyloidosis Current Treatment and Medical Practices

10. Hereditary Transthyretin Amyloidosis Unmet Needs

11. Hereditary Transthyretin Amyloidosis Emerging Therapies

12. Hereditary Transthyretin Amyloidosis Market Outlook

13. Country-Wise Hereditary Transthyretin Amyloidosis Market Analysis (2020-2034)

14. Hereditary Transthyretin Amyloidosis Market Access and Reimbursement of Therapies

15. Hereditary Transthyretin Amyloidosis Market Drivers

16. Hereditary Transthyretin Amyloidosis Market Barriers

17. Hereditary Transthyretin Amyloidosis Appendix

18. Hereditary Transthyretin Amyloidosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hereditary-transthyretin-amyloidosis-hattr-market-to-witness-promising-upswing-by-2034-delveinsight-forecasts-eidos-corino-prothena-ionis-pharma-astrazeneca-novo-nordisk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hereditary Transthyretin Amyloidosis (hATTR) Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Eidos, Corino, Prothena, Ionis Pharma, AstraZeneca, Novo Nordisk here

News-ID: 4207806 • Views:

More Releases from ABNewswire

Metastatic HR+/HER2 Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro
Metastatic HR+/HER2 Breast Cancer Market Positioned for Accelerated Development …
The Key Metastatic HR+/HER2 Breast Cancer Companies in the market include - Novartis, Arvinas, Olema Pharmaceuticals, Sichuan Baili Pharmaceutical, Ana C Garrido-Castro, MD, Fudan University, SynDevRx, Inc., Gilead Sciences, Puma Biotechnology, Inc., Adrienne G. Waks, Carrick Therapeutics Limited, and others. DelveInsight's "Metastatic HR+/HER2 Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Metastatic HR+/HER2 Breast Cancer, historical and forecasted epidemiology as well as the Metastatic
Hidradenitis Suppurativa Market Set for Robust Expansion Through 2034, DelveInsight Reports | AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeuti
Hidradenitis Suppurativa Market Set for Robust Expansion Through 2034, DelveInsi …
The Key Hidradenitis Suppurativa Companies in the market include - AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN Inc., Novartis, Phoenicis Therapeutics, Eli Lilly and Company, Beth Israel Deaconess Medical Center, Novartis, Sanofi, Boehringer Ingelheim, Incyte Corporation, and others. DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the
Woman-Owned Jete Brand Brings 20 Years of UX Design Excellence to Dance Apparel Industry with Inclusive Vision
Woman-Owned Jete Brand Brings 20 Years of UX Design Excellence to Dance Apparel …
Jete emerges as a game-changing force in dance apparel, leveraging its founder's unique combination of professional dance background and two decades of UX design expertise to create inclusive, sustainable fashion for dancers aged 3 to 99+. The print-on-demand brand launches with comprehensive sizing up to 5XL and a community-centered approach that celebrates dancers at every level. A new chapter begins in the dance apparel industry as Jete, operating under Rosa Digital
Fraysfield: Five Years of Resilience and Community Impact
Fraysfield: Five Years of Resilience and Community Impact
What began as Lisa Gregory's personal mission to build an e-commerce business that allowed her to work from home has grown into Fraysfield, a thriving shop built over the past five years. After her daughter's cancer diagnosis and survival, that mission expanded to include giving back, supporting the cancer society alongside other charitable causes. Fraysfield shows how small businesses can compete with major retailers by offering unique products, personalized service,

All 5 Releases


More Releases for Amyloidosis

Amyloidosis Market Massive Growth opportunity Ahead
Introduction Amyloidosis is a rare, progressive disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, leading to organ dysfunction and, in severe cases, life-threatening complications. The condition can affect the kidneys, heart, liver, and nervous system, making early detection and effective treatment essential. Historically underdiagnosed, amyloidosis is now gaining visibility due to advances in diagnostic tools, imaging technologies, and therapeutic innovations. In 2024, the global Amyloidosis Market is
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period? The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market? The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.. The transthyretin amyloidosis treatment market size is
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684 This latest report researches the industry structure,
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals